|Articles|June 15, 2003
Bausch & Lomb to delay regulatory filing
Rochester, NY-Bausch & Lomb will delay the regulatory filing for the intravitreal fluocinolone acetonide implant (Retisert), a treatment for diabetic macular edema (DME), for up to 3 years while the FDA reviews 12-month safety data of additional eyes treated with implants.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Related Articles
- The European Commission grants marketing authorization for EYLUXVI
September 23rd 2025
- Luxa Biotechnology announces clinical trial results for treatment of AMD
September 22nd 2025
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Idebenone accepted by FDA for priority review for Leber Hereditary Optic Neuropathy
2
Luxa Biotechnology announces clinical trial results for treatment of AMD
3
FDA approves abbreviated new drug application from Amneal Pharmaceuticals for bimatoprost ophthalmic solution 0.01%
4
The European Commission grants marketing authorization for EYLUXVI
5